Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated